Application of T-LAK cell-originated protein kinase (TOPK) serving as cisplatin resistance therapy target for cervical cancer

• Main Authors: MA HANLIN, QI GONGHUA, KONG BEIHUA, YUAN CUNZHONG
• Format: Patent
• Language: Chinese; English
• Published: 09.06.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of T-LAK cell-originated protein kinase (TOPK) serving as a cisplatin resistance therapy target for cervical cancer. In the prior art, a relationship between the TOPK and cervical cancer proliferation and cisplatin resistance is not yet studied. In order to clarify the mechanism of cisplatin resistance of cervical cancer patients, and provide a better therapeutic drug for the cervical cancer patients, the invention conducts a series of researches on the influences of TOPK on cervical cancer proliferation and cisplatin resistance. Results show that the TOPK is highly expressed in tissue of the cervical cancer patients, the TOPK promotes proliferation of cervical cancer cells, and overexpression of the TOPK promotes cisplatin resistance of the cervical cancer cells. A further study shows that a TOPK specific inhibitor OTS514 significantly inhibits proliferation of the cervical cancercells in vivo and in vit